Compare ITI Pharma and Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.87 |
NAV | ₹15.64 | ₹39.64 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹230.85 Cr | ₹6459.82 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.35
1.87
NAV
₹15.64
₹39.64
Fund Started
18 Oct 2021
25 Jun 2018
Fund Size
₹230.85 Cr
₹6459.82 Cr
Exit Load
Exit load of 0.50%, if redeemed within 3 months.
Exit load of 1% if redeemed within 15 days.
1 Year | -7.85% | 3.14% |
3 Year | 18.83% | 27.34% |
5 Year | - | 17.86% |
1 Year
-7.85%
3.14%
3 Year
18.83%
27.34%
5 Year
-
17.86%
Equity | 97.29% | 97.70% |
Cash | 2.71% | 2.30% |
Equity
97.29%
97.70%
Cash
2.71%
2.30%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 8.75% |
Apollo Hospitals Enterprise Ltd. | 6.12% |
Max Healthcare Institute Ltd. | 6.08% |
Torrent Pharmaceuticals Ltd. | 4.26% |
Aurobindo Pharma Ltd. | 4.02% |
Fortis Healthcare Ltd. | 3.60% |
Cohance Lifesciences Ltd. | 3.58% |
Lupin Ltd. | 3.25% |
Aster DM Healthcare Ltd. | 3.09% |
Sun Pharmaceutical Industries Ltd. | 12.83% |
Dr. Reddy's Laboratories Ltd. | 9.81% |
Cipla Ltd. | 8.00% |
Divi's Laboratories Ltd. | 7.48% |
Aurobindo Pharma Ltd. | 6.04% |
Lupin Ltd. | 5.70% |
Mankind Pharma Ltd. | 5.04% |
Alkem Laboratories Ltd. | 3.78% |
Syngene International Ltd. | 2.97% |
Cohance Lifesciences Ltd. | 2.68% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 06 Feb 2025 | 23 Feb 2021 |
Name
Dhimant Shah
Dharmesh Kakkad
Start Date
06 Feb 2025
23 Feb 2021
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
18 Oct 2021
25 Jun 2018